Newsroom
First PARADIGM4TB results published
The first results from UNITE4TB's flagship clinical trial, PARADIGM4TB, have been published in The New England Journal of Medicine (NEJM), marking a major milestone in the search for shorter, safer and more effective tuberculosis (TB) treatments.
The NEJM publication reports the results of the first stage of PARADIGM4TB, our innovative clinical trial designed to evaluate multiple TB treatment combinations in parallel. Of the ten experimental regimens assessed, two promising 16-week combinations have been selected for further investigation.
One contains ganfeborole, an investigational drug developed by GSK, while the other contains BTZ-043, developed by LMU University Hospital Munich and Leibniz-HKI.
Accelerating the search for better TB treatments
Through PARADIGM4TB, we're bringing together academic researchers, industry partners, clinical teams and TB community representatives to explore new approaches to TB drug development.
Our innovative multi-arm, multi-stage trial design allows several treatment combinations to be evaluated within a single clinical trial platform, helping us identify promising regimens more efficiently.
The next stage of PARADIGM4TB will investigate how much treatment duration can be shortened while maintaining long-term effectiveness and preventing the disease from returning. Further clinical evaluation will be needed before these regimens could become available to people affected by TB.
Sharing our results at the Union World Conference on Lung Health
The NEJM publication coincides with our dedicated symposium at the Union World Conference on Lung Health in Rio de Janeiro, Brazil, on 19 November 2026.
During the symposium, Reimagining TB drug development: Phase 2 results from the UNITE4TB platform, our team will explore the PARADIGM4TB results in greater detail, including primary outcomes, pharmacokinetics, resistance and biomarker analyses, alongside findings from our ENABLE trial.
This publication represents an important achievement for our consortium and partners, demonstrating the value of international collaboration and innovative clinical trial approaches in the search for better TB treatments.